SARS-CoV-2 B.1.526变异株在纽约市的快速出现与流行病学特征
纽约市卫生与心理卫生局分析2021年1月1日至4月5日实验室和流行病学数据,描述B.1.526变异株感染者的疾病严重程度、传播、再感染和突破感染情况。初步数据提示该变异株不导致更严重疾病,与接种后突破感染或再感染风险增加无关。因测序样本较少,统计效能可能不足以检测罕见结局的 modest 差异。
要点
- B.1.526变异株不导致更严重疾病。
- 该变异株与接种后突破感染风险增加无关。
- 该变异株与再感染风险增加无关。
核心结论
- 初步数据提示B.1.526变异株不导致更严重疾病,且与接种后突破感染或再感染风险增加无关。
研究设计与样本
- 纽约市卫生与心理卫生局分析实验室和流行病学数据,描述2021年1月1日至4月5日B.1.526感染病例特征。
主要发现
- B.1.526变异株包含在受体结合域携带E484K突变的亚分支,该突变可减弱多种SARS-CoV-2抗体的体外中和作用。
- 初步数据未显示B.1.526变异株导致更严重疾病或与突破感染、再感染风险增加相关。
临床怎么用
- 收集更大比例城市病例的及时病毒基因组数据并与基于人群的监测数据快速整合,以更好理解新发变异株和特定突变的影响。
局限性
- 研究期间测序标本相对较少,统计效能可能不足以检测突破感染或再感染等罕见结局的 modest 差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have documented the emergence and rapid growth of B.1.526, a novel variant of interest (VOI) of SARS-CoV-2, the virus that causes COVID-19, in the New York City (NYC) area after its identification in NYC in November 2020 (1-3). Two predominant subclades within the B.1.526 lineage have been identified, one containing the E484K mutation in the receptor-binding domain (1,2), which attenuates in vitro neutralization by multiple SARS-CoV-2 antibodies and is present in variants of concern (VOCs) first identified in South Africa (B.1.351) (4) and Brazil (P.1).* The NYC Department of Health and Mental Hygiene (DOHMH) analyzed laboratory and epidemiologic data to characterize cases of B.1.526 infection, including illness severity, transmission to close contacts, rates of possible reinfection, and laboratory-diagnosed breakthrough infections among vaccinated persons. Preliminary data suggest that the B.1.526 variant does not lead to more severe disease and is not associated with increased risk for infection after vaccination (breakthrough infection) or reinfection. Because relatively few specimens were sequenced over the study period, the statistical power might have been insufficient to detect modest differences in rates of uncommon outcomes such as breakthrough infection or reinfection. Collection of timely viral genomic data for a larger proportion of citywide cases and rapid integration with population-based surveillance data would enable improved understanding of the impact of emerging SARS-CoV-2 variants and specific mutations to help guide public health intervention efforts.
引用
- Thompson CN, Hughes S, Ngai S, et al. Rapid Emergence and Epidemiologic Characteristics of the SARS-CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33983915. doi:10.15585/mmwr.mm7019e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。